

Response to Reviewer:

Thank you for your valuable feedback on our manuscript. Please find below response to the comments

1) Please add the infectivity period of HAV and HEV.

Answer: Period added to the manuscript (Page 3, section disease phase)

2- Clarify the definition of relapsing HAV within how many months from disease onset.

Answer: Added to the manuscript (Page 3, section disease phase)

3- Add in short the countries with highest prevalence for HCV and HBV.

Answer: Data added to manuscript (Page 4 and 10, section epidemiology)

4- There is a more recent reference for the global incidence of HCV than the authors mentioned.

Answer: Reference updated in the manuscript (Page 10, section epidemiology)

5. What is the prevalence of different viral hepatitis in children? –

Answer: A paragraph added with prevalence of viral hepatitis in children (Page 3)

6. Please add a paragraph on prevention of HBV and HCV in perinatal transmission, needle prick injuries and household contacts. –

Answer: Paragraph added to manuscript (Page 13)

7. Discuss in short HBV vaccine schedules. Some developing countries recently adopt the zero dose of HBV vaccine especially if the mothers with unknown HBV status

Answer: Data added to manuscript (Page 8, section HBV vaccine and linkage care)

8- Please mention the best timing to start treatment for HBV and HCV in patients post liver transplant. –

Answer: Paragraph added to manuscript (Page 14)

9. Mention in short treatment options for HCV in children.

Answer: Paragraph and table added to manuscript (Page 10-11)

10- What are the treatment options for patients with HBV/HCV co-infection? –

Answer: Paragraph added to manuscript (Page 13-14)

11. Is there a role of sofosbuvir/ledipasvir in HCV genotype 4?

Answer: Data added to table 4